ACNPs combine the benefits of NPs and mAbs to provide high drug loads at the tumor site with better selectivity and delivery efficiency. The mAbs on the NP surfaces recognize their specific receptors expressed on the target cells and release the chemotherapeutic agent in a controlled manner. ...
Nanomedicine has been much heralded as a formulation-based approach to enhance the bioavailability of drug substances [5], [6]. Indeed, non-targeted nanoparticles containing current chemotherapies have now reached the market. They are generally liposomes, polymeric or metal nanoparticles. One of the...
Background:Antibody–drug conjugates (ADCs) require multiple assays to characterize their PK. These assays can separately evaluate the ADC by quantifying the antibody or the conjugated drug and may give different answers due to assay measurement differences, heterogeneous nature of ADCs and potential bi...
Full size image Next, to demonstrate the advantage of p-LFAs over an existing commercial US Food and Drug Administration (FDA) Emergency Use Authorization approved rapid, POC antigen testing method, we compared the analytical sensitivity of p-LFAs with the BD Veritor assay, which classified sampl...
From the perspectives of the full pharmacokinetic (PK) properties of ADC, three main components including (1) total antibody (tAb), (2) antibody-conjugated drug (acDrug)/(or conjugated antibody), and (3) free payload should be quantitated from in vivo samples [15]. Among these three main...
Recent research has been directed toward the use of monoclonal antibody-drug conjugates for solid tumors. In this study, we used the monoclonal antibody A7 to target the antitumor drug neocarzinostatin (NCS) to pancreatic cancer cells. The in vivo localization of the radiolabeled MAb A7 was ...
(OH)2) is administrated to the tumor-bear mice by applying a developed drug delivery strategy. Then, the main treatment is performed via selective delivery and controlled release of TXT as a cytotoxic drug. For selective delivery of Ca(OH)2and TXT to the cancer cells (caov-4 cells), a...
Background: TOR TOR, also known as FRAP1, is a member of the PI 3-Kinase-related Kinase (PIKK) family. It is the protein target of Rapamycin, an anti-rejection drug used in transplantation and a promising anti-cancer agent. TOR plays a crucial role in the control of cell growth and...
A recent study demonstrated that temporary inhibition of Myc selectively kills mouse lung cancer cells, making it a potential cancer drug target. Datasheet 说明书.pdf Sample Application Western blot analysis of c-Myc Recombinant protein with C-Myc-Tag Mouse Monoclonal Antibody-HRP conjugated ...
This product is sold under license from Millipore Corporation under the following US or foreign patents: 5,821,069; 5,658,791; EP0560890. This product shall not be used to commercially screen drug molecules being developed as JAK1 or JAK2 inhibitors. Any such activity will be outsi...